Andrew J. Dannenberg

Dr. Andrew J. Dannenberg


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
20 November 2018 in Nature Reviews Endocrinology
Verified
Journal Article
Closed access
PDF file
DQDaniela F. Quail
Daniela F. Quail
ADAndrew J. Dannenberg
Andrew J. Dannenberg

1 September 2001 in The Lancet Oncology
Verified
Journal Article
Closed access
ADAndrew J. Dannenberg
Andrew J. Dannenberg
NANasser K Altorki
Nasser K Altorki
JBJay O Boyle
Jay O Boyle
CDChau Dang
Chau Dang
LHLouise R Howe
Louise R Howe
KSKotha Subbaramaiah
Kotha Subbaramaiah

1 July 2011 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
PMPatrick G. Morris
Patrick G. Morris
CHClifford A. Hudis
Clifford A. Hudis
DGDilip Giri
Dilip Giri
MMMonica Morrow
Monica Morrow
DFDomenick J. Falcone
Domenick J. Falcone
ADAndrew J. Dannenberg
Andrew J. Dannenberg
Obesity is a risk factor for the development of hormone receptor–positive breast cancer in postmenopausal women and has been associated with an increased risk of recurrence and reduced survival. In humans, obesity causes subclinical inflammation in visceral and subcutaneous adipose tissue, characterized by necrotic adipocytes surrounded by macrophages forming crown-like structures (CLS). Recently, we found increased numbers of CLS, activation of the NF-κB transcription factor, and elevated aromatase levels and activity in the mammary glands of obese mice. These preclinical findings raised the possibility that the obesity → inflammation axis is important for the development and progression of breast cancer. Here, our main objective was to determine if the findings in mouse models of obesity translated to women. Breast tissue was obtained from 30 women who underwent breast surgery. CLS of the breast (CLS-B) was found in nearly 50% (14 of 30) of patient samples. The severity of breast inflammation, defined as the CLS-B index, correlated with both body mass index (P < 0.001) and adipocyte size (P = 0.01). Increased NF-κB binding activity and elevated aromatase expression and activity were found in the inflamed breast tissue of overweight and obese women. Collectively, our results suggest that the obesity → inflammation → aromatase axis is present in the breast tissue of most overweight and obese women. The presence of CLS-B may be a biomarker of increased breast cancer risk or poor prognosis. Cancer Prev Res; 4(7); 1021–9. ©2011 AACR.

1 December 2003 in Cancer Cell
Verified
Journal Article
Closed access
ADAndrew J. Dannenberg
Andrew J. Dannenberg
KSKotha Subbaramaiah
Kotha Subbaramaiah

14 November 2013 in Clinical Cancer Research
Verified
Journal Article
Closed access
PDF file
LHLouise R. Howe
Louise R. Howe
KSKotha Subbaramaiah
Kotha Subbaramaiah
CHClifford A. Hudis
Clifford A. Hudis
ADAndrew J. Dannenberg
Andrew J. Dannenberg
The increasing rate of obesity worldwide is predicted to be associated with a surge in diseases. Notably, obesity has been linked to approximately 20% of cancer cases in the United States; obesity is associated with both increased risk and worse outcomes after diagnosis. Altered levels of circulating factors are strongly implicated, including insulin, insulin-like growth factor 1, leptin, adiponectin, and interleukin-6 (IL-6). In addition, increasing attention has focused on the consequences of local adipose inflammation. Inflammatory foci characterized by crown-like structures consisting of dead adipocytes encircled by macrophages occur in white adipose depots, including the breast tissue, of most overweight and obese women. Saturated fatty acids, released as a consequence of obesity-associated lipolysis, induce macrophage activation via Toll-like receptor 4, thereby stimulating NF-κB signaling. This, in turn, activates transcription of proinflammatory genes including COX-2, IL-6, IL-1β, and TNFα. Elevated levels of proinflammatory mediators cause both local and systemic effects. Of particular relevance with regard to breast cancer is increased transcription of the CYP19 gene encoding aromatase, the rate-limiting enzyme for estrogen synthesis. Notably, this obesity–inflammation–aromatase axis provides a plausible explanation for increased rates of postmenopausal, hormone receptor–positive breast cancer associated with obesity and hence may offer targets for interventions to attenuate risk or improve prognosis. Potential approaches include weight reduction, exercise, and suppression of obesity-driven signaling pathways using pharmaceutical or dietary agents. A key future goal is to identify biomarkers that accurately report adipose inflammation, both for identification of at-risk individuals and to assess the efficacy of interventions. Clin Cancer Res; 19(22); 6074–83. ©2013 AACR.

1 March 2011 in Cancer Prevention Research
Verified
Journal Article
Closed access
PDF file
KSKotha Subbaramaiah
Kotha Subbaramaiah
LHLouise R. Howe
Louise R. Howe
PBPriya Bhardwaj
Priya Bhardwaj
BDBaoheng Du
Baoheng Du
CGClaudia Gravaghi
Claudia Gravaghi
ADAndrew J. Dannenberg
Andrew J. Dannenberg
Elevated circulating estrogen levels are associated with increased risk of breast cancer in obese postmenopausal women. Following menopause, the biosynthesis of estrogens through CYP19 (aromatase)-mediated metabolism of androgen precursors occurs primarily in adipose tissue, and the resulting estrogens are then secreted into the systemic circulation. The potential links between obesity, inflammation, and aromatase expression are unknown. In both dietary and genetic models of obesity, we observed necrotic adipocytes surrounded by macrophages forming crown-like structures (CLS) in the mammary glands and visceral fat. The presence of CLS was associated with activation of NF-κB and increased levels of proinflammatory mediators (TNF-α, IL-1β, Cox-2), which were paralleled by elevated levels of aromatase expression and activity in the mammary gland and visceral fat of obese mice. Analyses of the stromal-vascular and adipocyte fractions of the mammary gland suggested that macrophage-derived proinflammatory mediators induced aromatase and estrogen-dependent gene expression (PR, pS2) in adipocytes. Saturated fatty acids, which have been linked to obesity-related inflammation, stimulated NF-κB activity in macrophages leading to increased levels of TNF-α, IL-1β, and Cox-2, each of which contributed to the induction of aromatase in preadipocytes. The discovery of the obesity → inflammation → aromatase axis in the mammary gland and visceral fat and its association with CLS may provide insight into mechanisms underlying the increased risk of hormone receptor-positive breast cancer in obese postmenopausal women, the reduced efficacy of aromatase inhibitors in the treatment of breast cancer in these women, and their generally worse outcomes. The presence of CLS may be a biomarker of increased breast cancer risk or poor prognosis. Cancer Prev Res; 4(3); 329–46. ©2011 AACR.